The number of known novel platelet receptors/ligands that regulate the platelet activation cascade is growing. Recent studies demonstrated that scavengejr receptor class B, type I (SR-BI) is expressed on human and murine platelets. Importantly, reduced levels of platelet SR-BI expression are associated with increased platelet aggregation in patients. Total SR-Bl deficiency in mice on an apoE null background results in spontaneous myocardial infarction and premature death. Our preliminary studies showed that deficiency of SR-BI in murine platelets is also associated with remarkably increased platelet activation and aggregation in response to selected physiological agonists. In addition, we recently identified specific ligands for SR-BI that are potent inhibitors of integriri allbps activation andplatelet aggregation in vitro. Mechanisms linking SR-BI and allbB33 activation areniknown. Control of platelet reactivity is regarded as critical for prevention of acute cardiovascular events, thus the elucidation of mechanisms by which SR-BI may regulate integrin activation and whether it contributes to thrombotic events in vivo is important. It has been established that SR-BI may participate in signa ing events in several cell types. Moreover, CD36, a close relative of SR-BI, is associated in platelets wit i several protein-tyrosine kinases of theSrc family, Thus, we hypothesized that SR-BI-mediated signaling in platelets controls platelet integrin allbpS activation and, therefore, platelet aggregation and thrombosis. T ie long-term goal of this proposal is to determine the role platelet SR-BI is playing in thrombosis and to eluc date the exact molecular and cellular mechanisms of its contribution.
The specific Aims are:
Aim 1. To characterize the role cif SR-BI in integrin allb(33 activation andplatelet function in vitro.
Aim II. Toidentify the molecular signaling mechanisms linking SR-BI and activation of integrin allbft3 in platelets.
Aim III. Wewillseek to obtain evidence that platelet SR-BIplays a significant role in the regulation of platelet activation and thrombosis in vivo.
|Szpak, Dorota; Izem, Lahoucine; Verbovetskiy, Dmitriy et al. (2018) ?M?2 Is Antiatherogenic in Female but Not Male Mice. J Immunol 200:2426-2438|
|Plow, Edward F; Wang, Yunmei; Simon, Daniel I (2018) The search for new antithrombotic mechanisms and therapies that may spare hemostasis. Blood 131:1899-1902|
|Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Szpak, Dorota et al. (2018) The Kindlin-2 regulation of epithelial-to-mesenchymal transition in breast cancer metastasis is mediated through miR-200b. Sci Rep 8:7360|
|Gao, Detao; Podrez, Eugene A (2018) Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids. Free Radic Biol Med 115:57-67|
|Hirbawi, Jamila; Bialkowska, Katarzyna; Bledzka, Kamila M et al. (2017) The extreme C-terminal region of kindlin-2 is critical to its regulation of integrin activation. J Biol Chem 292:14258-14269|
|Ithychanda, Sujay S; Dou, Kevin; Robertson, Stephen P et al. (2017) Structural and thermodynamic basis of a frontometaphyseal dysplasia mutation in filamin A. J Biol Chem 292:8390-8400|
|Feng, Weiyi; Valiyaveettil, Manojkumar; Dudiki, Tejasvi et al. (2017) ?3 phosphorylation of platelet ?IIb?3 is crucial for stability of arterial thrombus and microparticle formation in vivo. Thromb J 15:22|
|Plow, Edward F (2017) An enlightening year in vascular biology. Curr Opin Hematol 24:222-223|
|Ding, Liang; Zhang, Lifang; Biswas, Sudipta et al. (2017) Akt3 inhibits adipogenesis and protects from diet-induced obesity via WNK1/SGK1 signaling JCI Insight 2:|
|Jawhara, Samir; Pluskota, Elzbieta; Cao, Wei et al. (2017) Distinct Effects of Integrins ?X?2 and ?M?2 on Leukocyte Subpopulations during Inflammation and Antimicrobial Responses. Infect Immun 85:|
Showing the most recent 10 out of 105 publications